The Motley Fool

Will Neil Woodford investors face a longer wait for cash after Eddie Stobart news?

Neil Woodford received a double dose of bad news on Friday morning. Haulage firm Eddie Stobart Logistics (LSE: ESL), in which Woodford is the largest shareholder, announced its shares would be suspended while accounting problems were investigated.

Meanwhile, the Woodford Patient Capital Trust (LSE: WPCT) said that after revaluing one of its largest holdings, the trust’s net asset value will be cut by 3.4p per share.

Claim your FREE copy of The Motley Fool’s Bear Market Survival Guide.

Global stock markets may be reeling from the coronavirus, but you don’t have to face this down market alone. Help yourself to a FREE copy of The Motley Fool’s Bear Market Survival Guide and discover the five steps you can take right now to try and bolster your portfolio… including how you can aim to turn today’s market uncertainty to your advantage. Click here to claim your FREE copy now!

Here, I’ll explain why today’s news could mean investors in the Woodford Equity Income fund will face further delays getting their cash back. I’ll also look at Patient Capital Trust and explain why I’m staying away, despite the stock’s discounted valuation.

What’s gone wrong at Eddie Stobart?

Eddie Stobart’s famous lorries are green and red. But shareholders are likely to be seeing only red after today’s news. The company says that after reviewing its half-year accounts with its auditors, it needs to apply “a more prudent approach” to certain accounting items.

Among the changes that will be made are fresh assessments of “the recoverability of certain receivables.” This suggests the group could be forced to write off some significant bad debts.

The impact of these changes is that adjusted operating profit for the half-year will be “significantly lower than anticipated.” Chief executive Alex Laffey has been replaced, with immediate effect.

Stobart is not yet able to provide updated figures, so its shares have been suspended to prevent a disorderly market. An amended set of accounts is expected to be ready in “early September,” when we can expect the shares to start trading again.

Bad news for Woodford

As I’ve said, Woodford is Eddie Stobart’s largest shareholder. His fund’s 22.9% shareholding was worth about £60m before today’s news, following a stock sale I estimate at £5.8m in early July. Stobart shares are likely to fall heavily when they return from suspension in September.

Woodford may find it difficult to find buyers for further large chunks of stock. I think these problems could add to his difficulties in reopening his Equity Income Fund in early December, as currently planned.

Patient Capital cuts valuation

Woodford’s other problem child is the Woodford Patient Capital Trust, which invests in early-stage companies. These are mostly loss-making businesses, hoping to commercialise new technologies or medical treatments.

Valuing investments of this kind is difficult and valuations are subject to regular revisions. That’s what’s happened today. In a statement this morning, the WPCT board said the trust’s valuation of Industrial Heat, a firm that aims to harness “cold fusion”, would be cut.

As a result, the WPCT net asset value will fall by 3.4p per share. The last reported net asset value for the trust was 78.96p, on 21 August. Today’s update suggests NAV could fall to about 75p when it’s next updated.

The Patient Capital Trust share price is currently about 42p. Although this represents a discount of nearly 50% to NAV, I think there’s a real risk further revaluations are likely over the coming weeks. In my view, WPCT looks like a potential value trap and remains a stock to avoid.

There’s a ‘double agent’ hiding in the FTSE… we recommend you buy it!

Don’t miss our special stock presentation.

It contains details of a UK-listed company our Motley Fool UK analysts are extremely enthusiastic about.

They think it’s offering an incredible opportunity to grow your wealth over the long term – at its current price – regardless of what happens in the wider market.

That’s why they’re referring to it as the FTSE’s ‘double agent’.

Because they believe it’s working both with the market… And against it.

To find out why we think you should add it to your portfolio today…

Click here to read our presentation.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.